Peer review

No Myth: CEO of ADC up­start calls it quits; Bris­tol My­ers vet Jon Wig­gin­ton scales new heights at Bright Peak

→ When Mythic Therapeutics CEO Alex Nichols spoke to Endpoints News last December about the biotech’s $103 million Series B, he and fellow co-founder Brian Fiske emphasized safety, saying that they’re “really working on trying to overcome what has been one of the most historically challenging obstacles to realizing the full potential of ADCs.” But Mythic will have to look for someone else to take up that mantle.

Just like start­ing over: Mod­er­na tees up an­oth­er CFO; Ge­of­frey Porges puts down his SVB pen to join Schrödinger

Moderna is hoping this CFO is the one that sticks.

The mRNA titan has poached James Mock from PerkinElmer, an appointment that Peer Review has been waiting on CEO Stéphane Bancel to make since the last hire took a strange turn in May. Jorge Gomez played finance chief for a day when Moderna was made aware of an investigation into his financial reporting practices by the company he just left, Dentsply Sirona. Gomez was out before he was ever really in, triggering yet another search for a CFO and delaying David Meline’s retirement.

As Covid pro­gram ad­vances, Enan­ta's new CMO says it's not 'lim­it­ed to an­tivi­ral­s'; With all eyes on Gilead-part­nered can­cer drugs, Ar­cus brings med­ical chief on board

Expect some pipeline adjustments at Enanta Pharmaceuticals in the coming years, because new CMO Scott Rottinghaus thinks the antiviral biotech can expand its horizons while also figuring out a way to address the yearslong Covid pandemic with an expected Phase II launch later this year.

“I would like to take a look at what we have as possibilities coming out of the lab. We have such a strong discovery program,” Rottinghaus told Endpoints News. “I don’t think we need to be limited to antivirals here at Enanta; we can take a broader look at some other therapeutic areas.”

Astel­las taps sea­soned CMO amid shift to on­col­o­gy; Doug Man­ion steps in­to a new Are­na fol­low­ing $6.7B buy­out

As Bernhardt Zeiher retires from Astellas’ chief medical officer position, the selection of his successor says a lot about the changes he’s seen at the company over his 12-year tenure.

Tadaaki Taniguchi, the new CMO, is a surgeon in oncology by training who’s led development for Merck, Bristol Myers Squibb and AstraZeneca in Japan before moving to the US, where he will be based. His most recent role at AstraZeneca was SVP, head of oncology business unit Asia strategy.

For­mer eGe­n­e­sis CEO joins vTv as it tries to make a come­back; Ei­sai nabs Alzheimer’s com­mer­cial ex­ec amid lecanemab push

While Rich Nelson is out as interim CEO of vTv Therapeutics, he will be continuing as the company’s EVP of corporate development as Paul Sekhri takes the mantle of president and CEO on Aug. 1.

In Nelson’s four short months as head of the North Carolina-based biotech, he saw G42 Healthcare, a UAE health tech company, invest in vTv and agree to collaborate on vTv’s Phase III study for a type I diabetes treatment. Prior to Nelson’s stepping in as CEO, Deepa Prasad had served as CEO, though she too was only there for a few months.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Ex-Mod­er­na com­mer­cial leader lands at Cel­sion as CEO; Schwan song: Chang­ing of the guard at Roche to take ef­fect next year

Less than 12 months into her job leading the commercial rollout of one of the world’s biggest-selling biotech products, Moderna’s Covid-19 vaccine, Corinne Le Goff departed the household name in December 2021, but her future in the industry is just now coming into clear view.

The more than 30-year industry veteran — whose posts have run the gamut across Pfizer, Sanofi, Merck, Roche and Amgenis now CEO and president of Celsion, which itself is potentially looking to get into the SARS-CoV-2 vaccine landscape, albeit way later than her previous employer.

For­mer Spark ex­ec to lead a gene ther­a­py up­start of his own; Big Phar­ma mar­ket­ing vet named CEO of Swiss biotech

Dave Greenwald’s days as acting CEO of Apertura Gene Therapy are over as Joseph La Barge steps in to lead the biotech, which just launched in April.

Peer Review had been wondering about La Barge’s next landing spot since he left Spark at the end of 2021. In his eight-year stretch with the gene therapy pioneer, he began as chief legal officer and was later promoted to CBO in 2019, when Spark was sold to Roche for $4.3 billion. Deerfield, where Greenwald is VP of business development, put up all the financing for Apertura’s $67 million Series A.

En­tos lures for­mer Plexxikon CEO to guide push to­ward the clin­ic; Ex-Bris­tol My­ers im­munol­o­gy chief finds new home

Around the same time that Entos CEO Tom Miller realized it was time to bring on a CSO to guide the company’s cancer drugs into the clinic, Daiichi Sankyo was winding down operations at its longtime subsidiary Plexxikon.

That led Miller to find Chao Zhang — Plexxikon’s former CEO who “couldn’t have been more tailor-made for driving our drug development program,” Miller said.

Zhang started at Entos earlier this week, after wrapping up a nearly 21-year career at Plexxikon.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Swat­ting away a takeover at­tempt, Zymeworks keeps re­tool­ing staff; Af­ter Cyg­nal-ing her ex­it from Flag­ship, Pearl Huang starts afresh

Zymeworks used a poison pill maneuver a couple weeks ago as the counterpunch to a $773 million takeover bid by All Blue Falcons, and new CEO Kenneth Galbraith isn’t done piecing the staff together either.

Paul Moore will end his 14-year association with MacroGenics, where he was VP, cell biology, and immunology, and step up to the plate as CSO of Zymeworks on July 18. Tony Polverino, the chief scientist who preceded Moore, didn’t escape the sweeping changes that were enacted by Galbraith in January, when half the C-suite and 25% of the staff overall received pink slips. Neil Klompas and Neil Josephson were named COO and CMO, respectively, and Chris Astle took over as CFO a month later.

Af­ter sev­en months of search­ing, Lan­dos hires a CEO; Mar­ty Du­vall re-emerges from ill-fat­ed On­copep­tides tenure

Landos Biopharma has landed a new CEO after seven months of being led by an interim chief executive.

Gregory Oakes took the helm of the autoimmune biotech this month, bringing with him nearly 30 years of industry chops, most recently as president of Vifor Pharma’s North America division and, before that, VP at Celgene. Oakes also spent a better part of the 2010s at Novartis, making his way up to head of biopharmaceuticals for generics division Sandoz.